Biomarker may affect chemo resistance in patients with advanced ovarian cancer
the ONA take:
miR-506, a non-coding RNA molecule that helps to control gene expression, may play a role in chemotherapy resistance in patients with ovarian cancer, according to a recent study published in the Journal of the National Cancer Institute.
Wei Zhang, PhD, of the MD Anderson Cancer Center and fellow researchers looked at patient data from The Cancer Genome Atlas and other independent clinical populations. In previous studies, they noted that the miR-506 molecule had the potential to sensitize cancer cells to chemotherapy.
In the present study, they found that response to chemotherapy drugs such as cisplatin and olaparib in epithelial ovarian cancer was significantly improved when miR-506 was added to the treatment.
“miR-506 was associated with better response to therapy and longer progression-free and overall survival,” Dr. Zhang said.
Previous studies found that the molecule was a potent inhibitor of epithelial-to-mesenchymal transition, which is associated with chemoresistance.
“This study provides further insight into this molecule’s role in augmenting chemotherapy responses by directly affecting the DNA repair process used by cancer cells to counter DNA damages caused by chemotherapy,” Dr. Zhang said.
miR-506 may play a role in chemotherapy resistance in patients with ovarian cancer.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- National Health Care Spending Expected to Grow Five Percent Annually
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- 1 Year of Adjuvant Trastuzumab Improves Long-Term DFS in Early Breast Cancer
- Lenalidomide Maintenance Appears Efficacious for Relapsed DLBCL
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|